Skip to main content

BiTE and ADCs for cancer therapy

Call for papers

This Journal of Hematology & Oncology series on bi-specific T-cell engagers (BiTE) and antibody-drug conjugates (ADCs) for cancer therapy is currently open for submissions.

Interested authors should submit their abstract to the Editorial Office.

Reviews, editorials, and first in-human clinical trial papers will be considered.

  1. Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, is approved for the treatment of newly-diagnosed CD33 + AML in adults and child...

    Authors: Jorge E. Cortes, Marcos de Lima, Hervé Dombret, Elihu H. Estey, Sergio A. Giralt, Pau Montesinos, Christoph Röllig, Adriano Venditti and Eunice S. Wang

    Citation: Journal of Hematology & Oncology 2020 13:137

    Content type: Review

    Published on: